| Therapeutic | Benmelstobart |
| Target | PDL1/CD274 |
| Heavy Chain | QITLKESGPTLVKPTQTLTLTCTVSGFSLSTYGVHWIRQPPGKALEWLGVIWRGVTTDYNAAFMSRLTITKDNSKNQVVLTMNNMDPVDTATYYCARLGFYAMDYWGQGTLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKAPKLLIYYAANRYTGVPDRFSGSGYGTDFTFTISSLQPEDIATYFCQQDYTSPYTFGQGTKLEIK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2023 |
| INN Year Recommended | 2023 |
| Companies Involved | Crown Bioscience, Apollomics, Chia Tai Tianqing Pharmaceutical Group, Chinese Academy of Medical Sciences, Fudan University, Shandong Cancer Hospital and Institute, Shanghai Tenth Peoples Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengda Tianqing Pharmaceutical Group Co. Ltd. |
| Conditions Approved | Small cell lung cancer |
| Conditions Active | Biliary cancer, Head and neck cancer, Non-small cell lung cancer, Ovarian cancer, Renal cancer, Diffuse large B cell lymphoma, Endometrial cancer, Gynaecological cancer, Hepatitis B, Hodgkin's disease, Liver cancer, Nasopharyngeal cancer, Squamous cell cancer, Acral lentiginous melanoma, Cholangiocarcinoma, Solid tumours |
| Conditions Discontinued | Triple negative breast cancer |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
